Biophan Reaches Major Milestone in Intellectual Property
Expands Biomedical Technology Portfolio to Total of 80 Patents, Licenses or Applications
Biophan Technologies, Inc. announced that the company's technology portfolio has swelled to 80 different patents, and pending patent applications either owned by Biophan or its licensors. The portfolio of groundbreaking technologies represents the world's most significant collection of intellectual property focused upon extending the safety, functionality, and compatibility of vital biomedical devices with magnetic resonance imaging (MRI), one of medicine's most important diagnostic imaging tools. The announcement was made by Michael Weiner, president and CEO of Biophan.
The Company has expanded its advanced technology portfolio 30% in the last 3 months alone, and the steep rate of technology acquisition is continuing. Biophan's patents and licenses involve several cutting-edge fields of research and development, including nanotechnology and biothermal battery technology.
"The future and success of Biophan lies in the commercialization of critically important and far-reaching science and technology. Biophan is at the forefront of this development," said Mr. Weiner. "It is extraordinary that we have been able to amass so much cutting-edge technology in such a short time, and we are excited by the vast market opportunities available for the products we're developing with this world-class portfolio of intellectual property." Our technology has the potential to impact millions of lives as biomedical devices are made safe for use with MRI, or are powered by biothermal batteries, or enhanced by drug delivery innovations.
Biophan recently announced a joint development agreement with the NASA Ames Research Center for Nanotechnology, Moffet Field, CA, for the characterization and development of high-density, nano-engineered thermoelectric materials for use with implantable medical devices.
Most read news
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.